Dear colleagues,
I attempted to establish a cardiac fibrosis model in SD rats using isoproterenol (freshly dissolved). I administered subcutaneous bolus injections at different concentrations (1–5 mg/kg) and in rats of different ages (200–600 g) 3 days consecutively. However, the mortality rate reached 75–90%, which is significantly higher than the rates reported in the literature.
Am I doing anything wrong? Or should I just abandon? Thanks!
Isoproterenol is a beta-adrenergic agonist commonly used to induce cardiac fibrosis in experimental animal models, including rats. Here's a brief overview of how it works:
Isoproterenol-Induced Cardiac Fibrosis Model
- Mechanism: Isoproterenol stimulates beta-adrenergic receptors, leading to increased heart rate, blood pressure, and cardiac workload. Prolonged exposure can cause cardiac remodeling, fibrosis, and hypertrophy.
- Dosage and Duration: Typically, rats are administered 50-100 mg/kg/day of isoproterenol subcutaneously for 1-4 weeks. However, the exact dosage and duration may vary depending on the study's objectives.
- Effects on Cardiac Tissue: Isoproterenol-induced cardiac fibrosis is characterized by
- Increased collagen deposition: Elevated levels of type I and III collagen lead to fibrosis and cardiac stiffness.
- Cardiomyocyte hypertrophy: Increased cell size and protein synthesis contribute to cardiac remodeling.
- Inflammation and oxidative stress.
Activation of various signaling pathways leads to inflammation and oxidative
Keep in mind that specific protocols and dosages may vary depending on the research question and study design.
- Badges
- Science topic
- Similar topics
- Biological Science
- Biochemistry
- Enzymology
- Enzymes